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Pupillary reflex abnormalities can result from disorders of the innervation or iris structure of 
the eye. In people with diabetes mellitus, the pupil size becomes smaller than normal due to 
neuropathy in innocent sympathetic innervation of the pupil. This neuropathy is associated as 
a manifestation of uncontrolled diabetes complications. Pupillary response is associated as a 
general indication of autonomic neuropathy disorders in diabetes mellitus patients. 
Apraclonidine as an ophthalmic sympathomimetic agent can cause mydriasis, which is likely 
to identify pupillary sympathetic denervation in type 2 diabetes mellitus patients. This study 
aimed to find out the correlation between HbA1c levels and pupillary response to 0.5% 
Apraclonidine eye drops in diabetes mellitus type 2 patients at Mohammad Hoesin Hospital 
Palembang. Observational research with a correlation test design to investigate the correlation 
of HbA1c levels with pupillary response to apraclonidine 0.5% eye drops in patients with type 
2 diabetes mellitus has been conducted from March to May 2019. The study sample met the 
inclusion and exclusion criteria of 31 diabetics mellitus type 2 with HbA1c level> 6.5% in the 
Eye clinic at the Mohammad Hoesin Palembang hospital. In this study 31 patients with type 2 
diabetes mellitus with HbA1c levels >6.5 mg% were obtained. The average HbA1c level was 
9.5 ± 1.4 mg%, which ranged from 7.6 - 12.6 mg%. The glycemic status of the patients in this 
study were all (100.0%) in an uncontrolled condition (HbA1c> 7.5 mg%). The estimated 
duration of diabetes mellitus is 2.7 ± 1.8 years, with a minimum value of 1 year and the largest 
being 8 years. The average change in pupillary diameter before - after dropping 0.5% 
apraclonidine was 1.16 ± 1.06 mm, ranging from 0 - 4 mm. There were 9 (29.0%) eyes that did 
not show any changes. Significant enlargement of pupillary size after dropping 0.5% 
apraclonidine (p = 0,000). This change in pupil size correlated with the estimated duration of 
diabetes mellitus (r = 0.436, p = 0.014) and HbA1c levels (r = 0.492, p = 0.005). Pupil size 
after using 0.5% apraclonidine has a distribution value of 4 (3-6) mm can be interpreted that 
there are subjects who have no change, but there are patients who have pupils dilated to 6 mm. 
 




Pupils are one of the eye organs that 
function to deliver light. Pupils will widen 
in dark room conditions and shrink when 
the room is bright. Pupil size is influenced 
by several factors including age, level of 
consciousness, strong irradiation, and level 
of accommodation. Changes in pupillary 
diameter are affected by sympathetic and 
parasympathetic fibers in the efferent 
pathway. The function of the sympathetic 
nerve is dilation of the pupil with a less 
significant effect on the ciliary muscle, 
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whereas the parasympathetic nerve 
functions for ciliary muscle contraction and 
the effect of accommodation. Thus, the 
pupillary diameter is determined by the 
antagonistic action of the pupillary 
sphincter and the dilator pupillary 
musculature. 1,2 
Directly or indirectly irradiating, the 
pupil normally experiences constriction 
called the pupillary reflex miosis. This 
constriction of the pupil aims to provide 
greater depth of focus because far and near 
objects are focused at the same time, and 
also to reduce all distortions produced by 
the lens. 1,2 Diabetes mellitus (DM) is a 
group of metabolic diseases characterized 
by hyperglycemia that occurs due to 
abnormal insulin secretion, insulin 
performance or both. Basic Health 
Research shows a significant increase in the 
prevalence of DM, from 6.9% in 2013 to 
8.5% in 2018; so the estimated number of 
people with DM in Indonesia reaches more 
than 16 million people who are then at risk 
of other diseases, such as: heart attack, 
stroke, blindness and kidney failure can 
even cause paralysis and death.  
According to WHO, DM is defined as a 
disease or chronic metabolic disorder with 
multi-etiology characterized by high blood 
sugar levels accompanied by impaired 
carbohydrate, lipid and protein metabolism 
as a result of insulin function insufficiency. 
According to data from the Palembang city 
health office, DM was ranked 8th in the list 
of 10 most diseases in 2017. It was later 
discovered that beta cell failure occurred 
earlier and was more severe than previously 
thought. In addition to muscle, liver and 
beta cells, other organs such as: fat tissue 
(increased lipolysis), gastrointestinal 
(incretin deficiency), alpha pancreas cells 
(hyperglucagonemia), kidneys (increased 
glucose absorption) and brain (insulin 
resistance), all of which play a role in 
causing the occurrence of impaired glucose 
tolerance in DM type. 2.3,4 
The diagnosis of DM must be based on 
checking blood glucose concentration. In 
determining the diagnosis of DM must be 
considered the origin of blood material 
taken and the method of examination used. 
One of the tests is the HbA1c examination 
which has been used as a diagnostic and 
monitor check in DM cases. Hemoglobin 
a1c (HbA1c) was initially identified as 
"unusual" hemoglobin in diabetic patients 
for 40 years and the HbA1c examination 
gave an indication of chronic glycemic 
events compared to being a glycemic test 
tool at one time.5,6 
Persistent hyperglycemia is considered 
a primary factor in diabetic neuropathy. 
This metabolic factor is not the only one 
responsible for the occurrence of diabetic 
neuropathy. There are other theories that 
are accepted, namely vascular theory, 
autoimmune and nerve growth factor. 
Some say that besides the role of glycemic 
control, the incidence of neuropathy is also 
associated with potential cardiovascular 
risks that can still be modified. ND 
manifestations can vary greatly, ranging 
from no complaints and can only be 
detected by electrophysiological 
examination, to severe pain complaints. It 
can also be a complaint in the form of local 
or systemic neuropathy, which all depends 
on the location and type of nerve affected 
by the lesion. 4-6 Neuropathy occurs in 7.5% 
of patients diagnosed with DM. More than 
half are distal symmetrical 
polyneuropathies. There is no racial 
predilection specifically for diabetic 
neuropathy. But black people are more 
likely to develop secondary complications 
from diabetic neuropathy, such as 
amputations of lower extremity than white 
people. DM regarding both men and 
women alike. However, male patients with 
type 2 diabetes can develop polyneuropathy 
earlier than women. Diabetic neuropathy is 
usually more common in the elderly.4,6 
Pupils are a good place to get 
information about the state of diabetic 
autonomic neuropathy because the 
innervation of pupils is exclusively 
autonomous and easily accessible for 
research without causing discomfort to the 
patient. In the study of A. Smith and S. E. 
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Smith, it was mentioned that type 2 DM 
patients had smaller pupil sizes than normal 
ones it may be due to neuropathy in innate 
sympathetic pupillary dilator so that 
pupillary reflex examination can be used to 
diagnose early diabetic neuropathy. In 
diabetic neuropathy patients, iris is often 
found damaged with lesions found in 
smooth muscle, connective tissue and 
blood vessels. Suggests other etiologies for 
small pupils such as local damage to the iris 
that inhibits iris movement. Another 
etiology is by conducting a pupillary 
response study with topical sympathometic 
administration in diabetic patients with or 
without small pupils. 
In the study of Fion D. Bremner and 
Stephen E. Smith mentioned that in general, 
pupils in patients with type 2 DM myosis, 
especially when it is dark. In a screening 
study, 21.7% of 359 type 2 DM patients 
found abnormal small pupillary sizes. The 
relationship between small pupil size and 
diabetes complications has been noted in 
several studies, such as the correlation with 
cardiovascular autonomic disorders 
mentioned in the study of Smith et al. In 
Heridarsson's research it was mentioned the 
relationship between small pupillary size 
and severe and chronic hyperglycemia. In 
one study mentioned, severe miosis was 
also found to be associated with 
supersensitivity to phenylephrine.3 In the 
Koc study, F et al found a similarity in 
sensitivity and specifications of 0.5% 
apraclonidine with topical cocaine to 
enforce Horner's syndrome. Topical 0.5% 
apaclonidine was found to have a dilating 
effect on pupils of Horner's syndrome 
patients. 3-5 
HbA1c examination has become a 
diagnostic examination for cases of type 2 
diabetes. HbA1c examination results 
provide an indication of chronic glycemic 
in DM type 2 patients. Thus, suspected in 
cases of DM with high levels of HbA1c 
consistency can also occur diabetic 
neuropathy. The application of 0.5% 
apraclonidine eye drops in the Koc F et al 
study provided pupillary responses in 
patients with Horner's syndrome who were 
found to have abnormalities in the 
sympathetic nerve pathway. This study 
aimed to find out about the correlation of 
HbA1c levels with pupillary response to 
0.5% Apraclonidine eye drops in patients 
with type 2 DM Mohammad Hoesin 
Hospital Palembang. The aim of this 
research is to determine the correlation of 
HbA1c levels with pupillary response to 






This study was an observational study 
with a correlation test design to investigate 
the correlation of HbA1c levels with 
pupillary response to apraclonidine 0.5% 
eye drops in patients with type 2 diabetes 
mellitus. This research was conducted at 
the hospital. Mohammad Hoesin Hospital 
Palembang between the period January 
2019 to March 2019.  
The study sample was people with type 
2 diabetes mellitus fulfilling the inclusion 
and exclusion criteria. In this study the 
sampling technique used was consecutive 
sampling. The inclusion criteria in this 
study are (a) Type 2 diabetes mellitus 
willing to participate in research that fills 
out and signs informed consent. While the 
exclusion criteria are if the patient has (a) 
History of glaucoma disease (b) History of 
use of anti-glaucoma eye drops (c) History 
of intraocular surgery (d) Are suffering 
from acute external eye infections and 
intraocular inflammation (e) Using contact 
lenses.  
All data is displayed in the form of 
tabulated data and performed statistical 
analysis using a computer program with the 
SPSS program. All variables in this study 
were analyzed univariately presented in the 
form of frequency distribution tables and 
narratives. while the correlation test used is 
the Spearman test. 
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In this study the dominant age distribution 
around 50-60 years was 17 (54.8%) 
subjects, age> 60 years there were 11 
(35.5%) subjects and 40-50 years were 3 
(9.7%). More male subjects than female 
subjects were actually 19 (61.3%) showed 
in Table 1. 
 
Table 1. Characteristic of Subject  






















HbA1c 9.51% ± 1.4 % 
Duration of DM 2 (1-8) years 
Pupil Size Before Using Apraclonidine 0.5% 3 (3-3) mm 
Pupil Size After Using Apraclonidine 0.5% 4 (3-6) mm 
Size of pupillary enlargement before and after 
using Apraclonidine 0.5% 
10 (0-4) mm 
*Normally distributed data are presented with mean ± standard deviation (SD), and abnormally distributed data are presented 
with a median (minimum-maximum) 
 
Bivariate correlation test analysis 
uses Spearman's Rho. There a significant 
correlation between pupillary size after the 
use of 0.5% apraclonidine and pupillary 
enlargement with HbA1c levels with 
moderate correlation. There is no 
significant relationship between duration of 
DM with HbA1c levels. can be seen in 
Table 4.3. There was a very significant 
relationship (p = 0,000) between pupil size 
after using 0.5% apraclonidine and 
pupillary enlargement with strong 
correlation strength (r = 1,000). And there 
is a significant relationship (p = 0.014) 
between the duration of DM with moderate 
correlation (can be seen in Table 2). 
 
Table 2. Analysis of pupillary response correlations with HbA1c levels 
 Kadar HbA1c 
Pupil Size After Using Apraclonidine 0.5% p = 0.005 
r = 0.492 
Size of pupillary enlargement before and after using Apraclonidine 
0.5% 
p = 0.005 
r = 0.492 
Duration of DM p = 0.064 
r = 0.337 
*Spearman's rho correlation test, significant value P <0.05, correlation strength value is very low if 0 - 0.199, 
correlation value is low if 0.20-0.39, moderate if 0.40 - 0.599, strong correlation value if 0.60- 0.799 and very 
strong if 0.80-1.00. 
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Table 3. Correlation analysis Pupil size after the use of 0.5% Apraclonidine with 
pupillary enlargement and duration of DM 
 Pupil Size After Using 
Apraclonidine 0.5% 
Size of pupillary enlargement before and after using Apraclonidine 
0.5% 
p = 0.000 
r = 1.000 
Duration of DM p = 0.014 
r = 0.436 
*Spearman's rho correlation test, significant value P <0.05, correlation strength value is very low if 0 - 0.199, 
correlation value is low if 0.20-0.39, moderate if 0.40 - 0.599, strong correlation value if 0.60- 0.799 and very 





This study aims to see changes in the 
size of the right eye pupils from before 
dropping 0.5% apraclonidine with 60 
minutes after dropping. Apraclonidine is an 
ophthalmic sympathomimetic agent 
pharmacologically belonging to the α2 
agonist group and although weaker it is also 
an α1 agonist. Apraclonidine in 0.5% and 
1% solutions has long been used clinically. 
1% solution is used to control or prevent 
increased postoperative intraocular 
pressure (IOP). Apraclonidine 0.5% is also 
used as a short-term adjunct agent to reduce 
IOP in glaucoma patients receiving 
maximum tolerated medical therapy. This 
drug was approved by the FDA in 1987.31 
For diagnostic purposes in the field of 
neuroophthalmology, apraclonidine has 
long been used to diagnose or confirm 
Horner's syndrome replaces cocaine 
solution which is more difficult to get.7-9 In 
this study 31 patients with type 2 DM with 
HbA1c levels> 6.5 mg% were obtained. 
The average HbA1c level was 9.5 ± 1.4 
mg%, which ranged from 7.6 - 12.6 mg%. 
The glycemic status of the patients in this 
study were all (100.0%) in an uncontrolled 
condition (HbA1c> 7.5 mg%). The 
estimated duration of DM is 2.7 ± 1.8 years, 
with a minimum value of 1 year and the 
largest being 8 years. 
 
Important findings in this study can be 
summarized as follows: 
a. Pupillary diameter in DM patients is 3 
mm (before apraclonidine 0.5%). 
b. Pupil diameter of 60 minutes after 
drops of 0.5% apraclonidine is 4.16 ± 
1.06 mm, which ranges from 3-7 mm. 
c. The average change in pupillary 
diameter before - after dropping 0.5% 
apraclonidine is 1.16 ± 1.06 mm, 
ranging from 0-4 mm. There were 9 
(29.0%) eyes that did not show any 
changes. 
d. Significant enlargement of pupillary 
size after 0.5% apraclonidine drop (p = 
0.000) 
e. This change in pupil size correlates 
with the estimated duration of DM (r = 
0.436, p = 0.014) and HbA1c levels (r 
= 0.492, p = 0.005). 
 
The pupil size of the patient before 
being given a 0.5% apraclonidine drop was 
obtained by 3 mm in the right eye of all the 
patients examined. This pupil size is still 
normal for adults, but in this study, we have 
no evidence whether this pupil size is 
smaller than the pupil size of patients 
before suffering from DM. In previous 
studies it was found that pupillary 
abnormalities in DM sufferers most often 
found are pupillary miosis. Other research 
also found a negative correlation between 
pupil size and duration of DM, the longer a 
person has DM the smaller the pupil 
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size.10,11 The most likely explanation for 
explaining the correlation between DM 
duration and myotic pupillary size, is due to 
denervation of the sympathetic nervous 
system in patients with DM, so that the 
amount of norepinephrine is not enough to 
trigger α1 receptors on the pupillary nerve. 
In general, normal pupillary size in 
adults ranges from 2 to 4 millimeters (mm) 
in diameter in bright light to 4 to 8 mm in 
the dark.2,3 Pupillary size in general can be 
said to be the resultant between sympathetic 
nervous system tone and nervous system 
parasympathetic to iris muscles. Pupil size 
depends on the intensity of the incoming 
light and the integrity of the components 
involved in the light reflex arch; 1) retina 
(receptor), 2) n.optikus (afferent fibers), 3) 
superior coliculus (center of light reflex), 4) 
autonomic system (efferent) 5) 
m.constrictor pupillae and m. pupillary 
dilator (effector).3,5-12 The parasympathetic 
system that supplies the eye originates from 
the nc.Edinger Westphal in the 
mesensefalon region whose fibers run in the 
nococomotorius (n.III) and travel to the 
ciliary ganglion to influence the 
accommodation function (m.ciliaris), 
secretion of the aquatic gland (ciliary 
gland) and consecration. pupil (m. 
constrictor pupillae). The parasymphatic 
nerve endings release acetylcholine as a 
neurotransmitter.7,12 
The symphatic system leading to the 
eyeball (oculosympathetic pathway) 
consists of a series of 3 neurons; first order 
neurons located in the hypothalamus, 
receive input from superior coliculus and 
send descending fibers to the thoracic 
intermediolateral horn (order II neurons), 
fibers from order II neurons are called 
praganglionic fibers, using acetylcholine as 
neurotransmitters travel to the symphatic 
intermediate caudal ganglion (neurons of 
order II), fibers from order II neurons are 
referred to as praganglionic fibers, using 
acetylcholine as neurotransmitters traveling 
towards the symphatic intermediate caudal 
ganglion (neurons of order II), fibers from 
order II neurons referred to as 
praganglionic fibers, using acetylcholine as 
neurotransmitters traveling towards the 
symphatic intermediate caudal ganglion 
(neurons of order II). III). Fibers from the 
superior cervical ganglion, called 
postganglionic fibers, travel together and 
follow the distribution of branches of the 
external and internal carotid arteries, one of 
which ends in the pupillary and corpus 
ciliary branches. Symphatic postganglionic 
fibers secrete norepinephrine as an 
adrenergic neurotransmitter.7,12 
In this study it was found that the 
majority of pupils (in 22 patients = 71.0%) 
experienced an increase in pupil size and in 
9 patients (29.0% found no change. 
Enlargement of pupil size that occurred had 
a median of 1 mm (ranging between 0 mm 
and 4 mm). Statistical analysis using the 
Wilcoxon test showed a significant increase 
in pupil size (p = 0,000), after 60 minutes a 
0.5% apraclonidine drop was applied. 
Spearman correlation analysis found a 
significant correlation between the increase 
in pupil size after 60 minutes of dropping 
0.5% apraclonidine with HbA1c levels (r = 
0.492, p = 0.005) and with the estimated 
duration of DM (r = 0.436, p = 0.014). In 
the multiple linear regression analysis, 
there was no effect of the age or gender of 
the patient on the change in size. To explain 
the correlation mechanism between 
increasing pupil diameter size and HbA1c 
levels and duration of DM, an analogy was 
examined using Horner's syndrome as a 
reference. The use of apraclonidine eye 
drops in Horner's syndrome has been 
widely reported. In Horner's syndrome, 
there is denervation of sympathetic nerve 
fibers in the oculo-sympathetic pathway 
resulting in pupillary anisocoria symptoms, 
ptosis and skin anhidrosis on the affected 
side. Reduced adrenergic stimulation of the 
pupillary m. dilator causes the pupil size to 
shrink (miosis). In an effort to compensate 
the body increases the number (up-
regulation) of α1 receptors in the muscle 
cells of the pupillary muscle, making them 
hypersensitive to adrenergic stimulation. 
Under hypersensitive conditions such as the 
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dropping of apraclonidine will trigger the 
pupillary muscle fibers resulting in 
enlargement of the pupil size, this condition 
is referred to as a positive apraclonidine 
test. Clinically seen as a loss, reduction of 
anisokoria or anisokoria reversal (from 
miosis to mydriasis). Some researchers 
report that in normal people, drops of 
apraclonidine solution in the eye do not 
cause mydriasis. 8,13 
In patients with DM also possible 
denervation in the oculo-sympathetic 
pathway leading to the eyeball. Decreased 
adrenergic (norepinephrine) stimulation of 
α1 receptors in the smooth muscle cells of 
the pupillary millillator is followed by 
compensatory efforts by up-regulation of 
α1 receptor protein expression. Increasing 
the number of postjunctional α1 receptors 
causes increased sensitivity of the pupillary 
muscle fibers response to apraclonidine 
0.5%. 
In general, adrenergic receptors are 
distinguished in 1) receptor α1 receptor, 
excitatory, β1 receptor (excitatory) and β2 
receptor (inhibitory) and 2) prejunctional: 
α2 receptor, inhibitory to norepinephrine or 
acetylcholine secretion. The number of α1 
receptors is far more than α2, so that in 
normal circumstances the release of 
norepinephrine in the iris will trigger the 
contraction of the m.dilator pupillae and the 
relaxation of the m.constrictor pupillae, 
resulting in mydriasis.8,14 In iris, 
apraclonidine is an agent that is agonizing 
(triggering) prejunctional α2 receptors and 
although weak is also an agonist for α1 
receptors. Under normal conditions, drops 
of apraclonidine do not cause significant 
changes in pupillary diameter in both dark 
and light conditions.14 In the state of 
oculosympathetic pathway denervation, as 
seen in Horner's syndrome, various studies 
have shown that apraclonidine can cause 
mydriasis. The main symptoms of Horner's 
syndrome are anisochorous pupils, ptosis 
and facial skin anhidrosis on the affected 
side. All of these symptoms are caused by 
damage (denervation) in the 
oculosympathetic pathway which causes 
not enough norepinephrine to trigger α1 
receptors and contraction of the m.dilator 
pupillae, while the parasympathetic 
pathway that triggers contraction of the 
m.constrictor pupillae is not disturbed so as 
a result there is a myosis of the problematic 
side eye.3,5,6 
The bad effects of DM on nerve fibers 
have been widely studied. Various 
pathomechanisms have been proposed to 
explain the occurrence of diabetic 
neuropathy, but simply the adverse effects 
due to DM stem from only 2 mechanisms, 
namely the adverse effects of prolonged 
hyperglycemia (glucotoxicity effect) and 
the adverse effects due to disruption of fat 
metabolism (lipotoxic effect). The longer a 
DM sufferer has uncontrolled 
hyperglycemia, the greater the impact of 
glucotoxicity and lipotoxic damage. 
Diabetic neuropathy in diabetics may occur 
in the form of somatosensory neuropathy, 
autonomic neuropathy or in a combination 
of both. autonomous to the system 
cardiovascular, nervous, reproductive, 
gastrointestinal and so on. DM affects the 
sympathetic nervous system and 
parasympathetic nerves, but the 
administration of apraclonidine 0.5% eye 
drops only affects the sympathetic nerve. 
This research can only answer the 
possibility of sympathetic denervation in 





There was a significant correlation (p 
= 0,000) between sizes pupils after using 
0.5% apraclonidine with enlargement 
pupils with a very strong correlation 
strength (r = 1,000). This study found that 
there was a correlation between HbA1c 
levels and pupillary response to 0.5% 
apraclonidine eye drops in type 2 diabetes 
mellitus, so that it could help as an early 
warning of possible sympathetic pupillary 
denervation. For further studies can use 
0.5% apraclonidine in detecting pupillary 
abnormalities in patients with type 2 
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diabetes mellitus controlled. It is 
recommended for further research to use 
pupillary measurements with pupillometry 
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